Caspofungin Side Effects
Not all side effects for caspofungin may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.
For the Consumer
Applies to caspofungin: intravenous powder for solution
In addition to its needed effects, some unwanted effects may be caused by caspofungin. In the event that any of these side effects do occur, they may require medical attention.
If any of the following side effects occur while taking caspofungin, check with your doctor or nurse immediately:More common
- Bloating or swelling of the face, arms, hands, lower legs, or feet
- blue lips, fingernails, or skin
- blurred vision
- changes in skin color
- chest pain
- convulsions (seizures)
- cracked lips
- decreased urine
- difficult or troubled breathing
- difficulty with swallowing
- dizziness, faintness, or lightheadedness when getting up from a lying or sitting position suddenly
- dry mouth
- increased thirst
- irregular heartbeat
- irregular, fast or slow, or shallow breathing
- loss of appetite
- mood changes
- muscle pain or cramps
- nausea or vomiting
- numbness or tingling in your hands, feet, or lips
- pain or redness at the injection site
- pain, tenderness, or swelling of the foot or leg
- pale skin
- pounding in the ears
- rapid weight gain
- shortness of breath
- slow or fast heartbeat
- sore throat
- sores, ulcers, or white spots on the lips, tongue, or inside the mouth
- tightness in the chest
- troubled breathing with exertion
- unusual bleeding or bruising
- unusual tiredness or weakness
- unusual weight gain or loss
- Bloody urine
- decreased frequency or amount of urine
- increased blood pressure
- lower back or side pain
- weight gain
- yellow eyes or skin
- Abdominal or stomach pain or tenderness
- black, tarry stools
- bladder pain
- bleeding gums
- blood in the urine or stools
- bloody nose
- chest pain or discomfort
- clay-colored stools
- cloudy urine
- dark urine
- decreased appetite
- fever with or without chills
- flushed, dry skin
- frequent urge to urinate
- fruit-like breath odor
- general feeling of tiredness or weakness
- incoherent speech
- increased hunger
- increased urination
- light-colored stools
- metallic taste
- muscle spasms (tetany) or twitching seizures
- muscle weakness
- no blood pressure or pulse
- noisy, rattling breathing pain or discomfort in arms, jaw, back, or neck
- pains in stomach, side, or abdomen, possibly radiating to the back
- pinpoint red spots on skin
- rapid, shallow breathing
- rapid weight gain
- right upper abdominal or stomach pain and fullness
- shakiness in the legs, arms, hands, or feet
- stomach pain, continuing
- stopping of heart
- trembling or shaking of hands or feet
- troubled breathing at rest
- ulcers, sores, or white spots in the mouth
- unexplained weight loss
- unpleasant breath odor
- vomiting of blood
- weight loss
Some of the side effects that can occur with caspofungin may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:More common
- Flushing, redness of skin
- unusually warm skin
- Acid or sour stomach
- back pain
- blistering, peeling, or loosening of skin
- bumps on skin
- difficulty in moving
- dry, red, hot, or irritated skin
- flaking and falling off of skin
- full or bloated feeling
- hives or welts
- joint or muscle pain
- lack or loss of strength
- muscle pain or stiffness
- pressure in the stomach
- red skin lesions, often with a purple center
- red, irritated eyes
- redness of skin
- sleepiness or unusual drowsiness
- small red or purple spots on skin
- stomach discomfort, upset, or pain
- swelling of abdominal or stomach area
- trouble sleeping
- unable to sleep
For Healthcare Professionals
Applies to caspofungin: intravenous powder for injection
Gastrointestinal side effects have included diarrhea (up to 27%), vomiting (up to 17%), nausea (up to 15%), and abdominal pain (up to 9%). Anorexia, abdominal distension, upper abdominal pain, constipation, and dyspepsia have been reported in less than 5% of patients. Pancreatitis has been reported during postmarketing experience.
Other side effects have included fever (up to 40%), infusion-related adverse reactions (defined as a systemic event, such as flushing, fever, chills, hypotension, hypertension, tachycardia, dyspnea, tachypnea, rash, or anaphylaxis; up to 35%), chills (up to 23%), septic shock (up to 14%), aspergillosis (13%), peripheral edema (up to 11%), sepsis (up to 7%), mucosal inflammation (up to 6%), flu-like illness, malaise, pain, and warm sensation. Asthenia, fatigue, edema, flushing, and bacteremia have been reported in less than 5% of patients. Swelling has been reported during postmarketing experience.
Metabolic side effects have included decreased blood potassium (up to 23%), increased blood alkaline phosphatase (up to 22%), hypokalemia (up to 10%), decreased blood albumin (up to 8.6%), decreased blood magnesium (up to 7%), increased blood glucose (6%), decreased total serum protein (3.1%), and elevated serum calcium (1.1%). Decreased appetite, fluid overload, hypomagnesemia, hypercalcemia, and hyperglycemia have been reported in less than 5% of patients.
A 68-year-old male experienced reversible severe thrombocytopenia coincident with caspofungin therapy. He was admitted for shortness of breath, coughing, abdominal pain, and intermittent fever, which had persisted for 10 days. Two blood cultures obtained on admission revealed Candida albicans. He was given caspofungin 70 mg for 1 day, then 50 mg per day. One week after receiving caspofungin therapy, his platelet count dropped precipitously from 136 x 10(3)/mm3 to 24 x 10(3)/mm3, reaching a nadir at 3 x 10(3)/mm3 in 2 days. Caspofungin was discontinued, and his platelet count returned to a level above 150 x 10(3)/mm3 within 10 days.
Hematological side effects have included decreased hemoglobin (up to 21%), decreased hematocrit (up to 18%), decreased white blood cell count (up to 12%), anemia (up to 11%), eosinophilia (2.3% to 3.2%), decreased platelets (1.5% to 3.1%), and hypoalbuminemia (common). Thrombocytopenia, coagulopathy, febrile neutropenia, and neutropenia have been reported in less than 5% of patients.
Respiratory side effects have included respiratory failure (up to 20%), cough (up to 11%), pneumonia (up to 11%), pleural effusion (9%), dyspnea (up to 9%), and rales (7%). Tachypnea, epistaxis, and hypoxia have been reported in less than 5% of patients. Pulmonary edema, adult respiratory distress syndrome, and pulmonary infiltrates have been reported infrequently.
Cardiovascular side effects have included hypotension (up to 20%), tachycardia (up to 8%), and hypertension (up to 6%). Arrhythmia, atrial fibrillation, bradycardia, cardiac arrest, and myocardial infarction have been reported in less than 5% of patients.
Reported elevations in ALT and AST were accompanied by the use of cyclosporine in some of the patients enrolled in the clinical trials.
Hepatic side effects have included elevations in ALT (up to 18%), AST (up to 17%), blood bilirubin (up to 13%), and conjugated bilirubin (up to 8%). Hepatic failure, hepatomegaly, hepatotoxicity, hyperbilirubinemia, and jaundice have been reported in less than 5% of patients. Isolated cases of clinically significant hepatic dysfunction and hepatitis have also been reported. Hepatic necrosis has been reported during postmarketing experience.
Local side effects have included phlebitis (up to 25%), thrombophlebitis (11.3% to 15.7%), and infused vein complications (1.5% to 12%). Infusion site pain, infusion site pruritus, and infusion site swelling have been reported in less than 5% of patients.
Dermatological side effects have included rash (up to 23%), pruritus (up to 7%), decubitus ulcer (up to 5%), erythema (up to 5%), induration (3.1%), and sweating (1.3%). Petechiae, skin lesion, and urticaria have been reported in less than 5% of patients. At least one case of toxic epidermal necrolysis has been reported. Erythema multiforme, Stevens-Johnson syndrome, and skin exfoliation have been reported during postmarketing experience.
Nervous system side effects have included headache (up to 15%) and paresthesia (1.3% to 3.1%). Convulsion, dizziness, somnolence, and tremor have been reported in less than 5% of patients.
Renal side effects have included increased blood creatinine (up to 11%), increased blood urea nitrogen (up to 9%), nephrotoxicity (3%), and renal failure (less than 5%). Clinical renal events, regardless of causality, have been reported in 13% of patients. Clinically significant renal dysfunction has been reported during postmarketing experience.
Hypersensitivity side effects have included anaphylaxis and possible histamine-mediated symptoms (including reports of rash, facial swelling, angioedema, pruritus, sensation of warmth, or bronchospasm).
Genitourinary side effects have included urine positive for red blood cells (10%) and an increase in urine white blood cells (7.7%), protein (1.2% to 4.9%), and red blood cells (1.1% to 3.8%). Urinary tract infection and hematuria have been reported in less than 5% of patients.
Psychiatric side effects have included anxiety, confusional state, depression, and insomnia in less than 5% of patients.
Musculoskeletal side effects have included myalgia (3.1%) and musculoskeletal pain (1.3%). Arthralgia, back pain, and pain in extremity have been reported in less than 5% of patients.
More about caspofungin
- Other brands: Cancidas
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.